This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LY929

Ligand Pharmaceuticals, Inc.

Drug Names(s): LY-510929

Description: LY929 is a dual peroxisome proliferation activated receptor (PPAR) alpha and gamma agonist.

Deal Structure: The Lilly-Ligand collaboration involving PPAR modulators began in 1997.

Under the terms of the collaboration, Ligand receives research funding from Lilly. Lilly is responsible for the development and registration of any products resulting from the collaboration, and pays Ligand milestone payments as products move through the development process. Lilly has exclusive worldwide marketing rights to products resulting from the research, and will pay Ligand royalties on sales of products that make it to market.

Partners: Eli Lilly & Company


LY929 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug